Neurobiology/Psychopharmacology (PMHNP) – Based on Stahl’s Essential Psychopharmacology, 5th Edition (2021)

These notes focus on the core neuroscientific basis from Stahl’s book, tailored for PMHNP students. They emphasize mechanisms relevant to psychiatric disorders and psychotropic medications. Stahl uses a unique visual language with icons and figures—review those in the text for better retention.
Chapter 1: Chemical Neurotransmission
Core Concept: Modern psychopharmacology is the story of chemical neurotransmission. Neurons communicate electrically within themselves but chemically between each other at synapses.
Key Processes:

Anatomical vs. Chemical Basis: The brain is a network of neurons connected by synapses (axodendritic, axosomatic, axoaxonic). Communication is unidirectional (anterograde).
Excitation-Secretion Coupling: Action potential arrives at presynaptic terminal → voltage-gated Ca²⁺ channels open → Ca²⁺ influx → vesicle fusion → neurotransmitter (NT) release into synaptic cleft.
NT Actions: Bind postsynaptic receptors → signal transduction → postsynaptic potential (excitatory or inhibitory).
Termination: Reuptake (transporters), enzymatic degradation, or diffusion.
Neuroplasticity: Synaptic strength changes (LTP/LTD) via gene expression, second messengers, and structural remodeling. Critical for learning, memory, and treatment response.

Major Neurotransmitter Systems (targets of most psychotropics):

Glutamate (excitatory, major): AMPA/NMDA/kainate receptors.
GABA (inhibitory, major): GABA-A (ionotropic), GABA-B (metabotropic).
Dopamine (DA): Reward, motivation, psychosis.
Serotonin (5-HT): Mood, anxiety, sleep.
Norepinephrine (NE): Arousal, attention, stress.
Acetylcholine (ACh): Cognition, memory (basal forebrain, hippocampus).

Clinical Relevance: Psychiatric disorders involve circuit dysfunction (e.g., hypoactive prefrontal cortex in depression/schizophrenia). Drugs restore balance via modulation of these systems.
Chapter 2: Transporters, Receptors, and Enzymes as Targets of Psychopharmacological Drug Action
Key Drug Targets:

Transporters (reuptake pumps): SERT (serotonin), NET (norepinephrine), DAT (dopamine). SSRIs, SNRIs, stimulants block these → ↑ synaptic NT.
Receptors:
G-Protein Coupled Receptors (GPCRs): Metabotropic; slow, modulatory (e.g., 5-HT1A, D2, alpha/beta adrenergic). Activate second messengers (cAMP, IP3, DAG).
Ligand-Gated Ion Channels (ionotropic): Fast (e.g., GABA-A, nicotinic ACh, 5-HT3).

Enzymes: MAO (monoamine oxidase), COMT (catechol-O-methyltransferase), AChE. Inhibitors (e.g., MAOIs) ↑ NT levels.

Pharmacodynamics Concepts:

Agonist: Full activation.
Partial Agonist: Submaximal activation (e.g., aripiprazole at D2 – stabilizes dopamine).
Antagonist: Blocks agonist.
Inverse Agonist: Reduces constitutive activity.
Allosteric Modulators: Bind different site, alter function (e.g., benzodiazepines on GABA-A).

Side Effects Prediction: Receptor affinity profiles (e.g., H1 antagonism → sedation/weight gain; M1 → cognitive issues; alpha-1 → orthostasis).
Chapter 3: Ion Channels as Targets of Psychopharmacological Drug Action

Ligand-Gated Ion Channels (Ionotropic Receptors): NT opens channel directly (fast transmission).
Examples: GABA-A (Cl⁻ influx, inhibitory), NMDA (Ca²⁺, excitatory – glutamate + glycine + depolarization).

Voltage-Sensitive Ion Channels (VSICs): Opened by membrane potential.
Na⁺, K⁺, Ca²⁺ channels. Targets for some anticonvulsants/mood stabilizers.

Clinical Notes: Many psychotropics modulate these for rapid effects (e.g., benzodiazepines enhance GABA-A Cl⁻ conductance).
Chapter 4: Psychosis, Schizophrenia, and the Neurotransmitter Networks (Dopamine, Serotonin, Glutamate)
Neurotransmitter Networks:

Dopamine Hypothesis (updated): Hyperactive mesolimbic DA → positive symptoms; hypoactive mesocortical DA → negative/cognitive symptoms.
Serotonin-Glutamate Interaction: 5-HT2A antagonism modulates glutamate.
Key Circuits: Mesolimbic (reward/psychosis), mesocortical (cognition), nigrostriatal (EPS), tuberoinfundibular (prolactin).

Schizophrenia Pathophysiology: Dysconnectivity, NMDA hypofunction (glutamate), excess DA in certain pathways, neurodevelopmental issues.
Chapter 5: Targeting Dopamine and Serotonin Receptors – “Antipsychotics”

First-Generation (Typical): Strong D2 antagonists → good for positive symptoms but high EPS/tardive dyskinesia risk.
Second-Generation (Atypical): D2 + 5-HT2A antagonism → better negative symptoms, lower EPS.
Third-Generation: Partial agonists (e.g., aripiprazole, brexpiprazole) – dopamine stabilizers.
Newer agents cover Parkinson’s psychosis, dementia behaviors.

Monitoring: Metabolic syndrome, EPS, QTc, prolactin.
Mood Disorders (Chapters 6–7-ish)
Depression Networks: Monoamine deficiency (NE, 5-HT, DA), HPA axis hyperactivity, neuroinflammation, reduced neuroplasticity (BDNF ↓).

Antidepressants:
SSRIs/SNRIs: Reuptake inhibition.
Atypical: Bupropion (NDRI), mirtazapine (alpha-2, 5-HT2/3 antagonist).
Others: Vortioxetine (multimodal 5-HT), MAOIs, TCAs.

Bipolar: Mood stabilizers (lithium – GSK-3, inositol; valproate, lamotrigine), antipsychotics.

Key: Delayed onset due to downstream neuroplastic changes (gene expression, synaptogenesis).
Anxiety, Trauma, OCD, PTSD

GABA Hypofunction or excessive glutamate/NE.
Treatments: SSRIs/SNRIs (first-line), benzodiazepines (short-term), buspirone (5-HT1A), prazosin (alpha-1 for nightmares).

Other Key Topics

ADHD: DA/NE dysregulation in prefrontal cortex. Stimulants (block DAT/NET), atomoxetine (NRI), guanfacine/clonidine (alpha-2 agonists).
Sleep/Wake Disorders: Orexin, histamine, melatonin pathways. Hypnotics target GABA-A; wake promoters (modafinil) affect DA.
Dementia/Cognition: ACh deficits (donepezil), memantine (NMDA antagonist).
Addiction: Reward circuit (DA) hijacking.

Neuroplasticity & Epigenetics: Long-term treatment effects via BDNF, CREB, histone acetylation. Explains why meds take weeks and why psychotherapy + meds synergize.
Practical Applications for PMHNP

Prescribing Principles: Match drug mechanism to patient symptoms/circuit dysfunction. Start low, go slow, monitor side effects via receptor profiles.
Evidence-Based: Combine with psychotherapy; consider pharmacogenomics (CYP450, e.g., 2D6, 2C19).
Special Populations: Pediatrics, geriatrics, pregnancy – adjust for pharmacokinetics.

Study Tips:

Master Stahl’s figures/icons for visual recall.
Link mechanisms → symptoms → drug choice → side effects.
Review with Prescriber’s Guide companion for dosing/clinical pearls.
Practice: For a patient with depression + anxiety, why SNRI over SSRI? (Broader monoamine coverage.)